

Timothy Price

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4273626/publications.pdf>

Version: 2024-02-01

264
papers

19,573
citations

38742

50
h-index

11607

135
g-index

267
all docs

267
docs citations

267
times ranked

20956
citing authors

#	ARTICLE	IF	CITATIONS
1	Postpancreatectomy Acute Pancreatitis (PPAP). <i>Annals of Surgery</i> , 2022, 275, 663-672.	4.2	56
2	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 39-51.	2.4	0
3	Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 428-433.	1.1	0
4	Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. <i>Targeted Oncology</i> , 2022, 17, 35-41.	3.6	3
5	VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. <i>Scientific Reports</i> , 2022, 12, 1238.	3.3	7
6	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 115-124.	10.7	147
7	Immunotherapy use in oesophagogastric cancers—a review of the literature. <i>British Journal of Cancer</i> , 2022, 127, 21-29.	6.4	2
8	Insights From the IDEA Collaboration: Are They Enough?. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102975.	1.6	1
9	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. <i>Targeted Oncology</i> , 2022, 17, 95.	3.6	2
10	Targeting Mutated KRAS Genes to Treat Solid Tumours. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 39-49.	3.8	13
11	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4122-4122.	1.6	11
12	SPAR: A randomized placebo-controlled phase 2 trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: An AGITG clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3646-TPS3646.	1.6	0
13	Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreak100.. <i>Journal of Clinical Oncology</i> , 2022, 40, 102-102.	1.6	14
14	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	5.1	77
15	Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 203-210.	3.0	5
16	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100637.	2.0	11
17	Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 52-59.	7.0	12
18	Curative therapy for rectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 193-203.	2.4	7

#	ARTICLE	IF	CITATIONS
19	Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 131-138.	1.1	19
20	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. <i>Journal of Clinical Oncology</i> , 2021, 39, 17-29.	1.6	58
21	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. <i>Clinical Cancer Research</i> , 2021, 27, 2159-2167.	7.0	9
22	Immunohistochemistry features and molecular pathology of appendiceal neoplasms. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 369-384.	6.1	5
23	Female breast cancer treatment and survival in South Australia: Results from linked health data. <i>European Journal of Cancer Care</i> , 2021, 30, e13451.	1.5	3
24	The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. <i>Patient Education and Counseling</i> , 2021, 105, 212-220.	2.2	1
25	Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 681-693.	2.5	0
26	Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4115-4115.	1.6	0
27	Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021, 384, 2371-2381.	27.0	833
28	Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-PyMt mouse mammary tumours. <i>BMC Cancer</i> , 2021, 21, 736.	2.6	3
29	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. <i>Clinical Colorectal Cancer</i> , 2021, 20, 245-255.	2.3	2
30	COVID-19 prompts rapid and safe transition of chemotherapy into homes. <i>Australian Health Review</i> , 2021, , .	1.1	1
31	A systematic scoping review of determinants of multidisciplinary cancer team access and decision-making in the management of older patients diagnosed with colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 909-916.	1.0	2
32	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1152-1162.	3.0	6
33	Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry. <i>Targeted Oncology</i> , 2020, 15, 751-757.	3.6	8
34	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. <i>Cancer Biology and Therapy</i> , 2020, 21, 891-898.	3.4	14
35	<i>KRAS</i> ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	27.0	1,049
36	Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age. <i>Breast Cancer Research</i> , 2020, 22, 90.	5.0	11

#	ARTICLE	IF	CITATIONS
37	Anti-Angiogenic Properties of Ginsenoside Rg3. <i>Molecules</i> , 2020, 25, 4905.	3.8	50
38	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 3662-3670.	7.0	107
39	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. <i>PLoS ONE</i> , 2020, 15, e0229900.	2.5	12
40	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	2.4	4
41	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 305-324.	2.4	0
42	Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study. <i>BMJ Open</i> , 2020, 10, e037069.	1.9	4
43	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. <i>Cancers</i> , 2020, 12, 1715.	3.7	7
44	Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 3-12.	1.1	1
45	CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS ^{G12C} , in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4018-4018.	1.6	22
46	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of ¹⁷⁷ Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and tumors (pNETS, mNETS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4608-4608.	1.6	15
47	First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of ¹⁷⁷ Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).. <i>Journal of Clinical Oncology</i> , 2020, 38, 604-604.	1.6	12
48	Phase I trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma (ART in LAP).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16796-e16796.	1.6	0
49	Regorafenib outcomes from the population-based South Australian mCRC registry (SAmCRCR).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19344-e19344.	1.6	0
50	Prognostic differences of RAS mutations: Results from South Australian (SA) metastatic colorectal (mCRC) registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4067-4067.	1.6	5
51	Cohort 1 results of a phase I study of autolytic immunotherapy of metastatic neuroendocrine neoplasms using intralesional rose bengal disodium.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16694-e16694.	1.6	0
52	403â€¦Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors. , 2020, , .		0
53	Stereoselective Anti-Cancer Activities of Ginsenoside Rg3 on Triple Negative Breast Cancer Cell Models. <i>Pharmaceuticals</i> , 2019, 12, 117.	3.8	34
54	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 341.	1.9	39

#	ARTICLE	IF	CITATIONS
55	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , 2019, 575, 217-223.	27.8	1,375
56	Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. <i>Molecules</i> , 2019, 24, 3539.	3.8	24
57	Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. <i>Targeted Oncology</i> , 2019, 14, 85-91.	3.6	10
58	Moving miRNAs to therapeutic targets in colorectal cancer. <i>EBioMedicine</i> , 2019, 43, 13-14.	6.1	1
59	Authors' Reply to Yu: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry" <i>Targeted Oncology</i> , 2019, 14, 367-368.	3.6	0
60	Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1818.	4.1	20
61	Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. <i>Epigenetics</i> , 2019, 14, 158-170.	2.7	7
62	First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-14.	1.1	4
63	Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival. <i>BMJ Open</i> , 2019, 9, e031421.	1.9	24
64	SPAR " a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. <i>BMC Cancer</i> , 2019, 19, 1229.	2.6	15
65	Outcomes of Older Patients (>= 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , 2019, 18, e140-e149.	2.3	5
66	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. <i>Clinical Colorectal Cancer</i> , 2019, 18, 141-148.	2.3	19
67	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. <i>Clinical Cancer Research</i> , 2019, 25, 1216-1225.	7.0	35
68	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 520-529.	4.2	189
69	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11023-11023.	1.6	9
70	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRAS(G12C) inhibitor, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3003-3003.	1.6	145
71	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3518.	1.6	5
72	A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4102-4102.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. Journal of Clinical Oncology, 2019, 37, 537-537.	1.6	2
74	Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. Journal of Clinical Oncology, 2019, 37, 638-638.	1.6	4
75	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Research Protocols, 2019, 8, e14361.	1.0	3
76	Type 2 diabetes as a potential risk marker for early onset colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15005-e15005.	1.6	2
77	Atezolizumab for the treatment of colorectal cancer: <i>the latest evidence and clinical potential</i>. Expert Opinion on Biological Therapy, 2018, 18, 449-457.	3.1	25
78	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 2018, 18, 339-349.	2.4	6
79	Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia. Hpb, 2018, 20, 340-346.	0.3	10
80	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 263-270.	8.1	121
81	Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. Cancer Treatment Reviews, 2018, 66, 1-6.	7.7	26
82	Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer. Lancet Oncology, The, 2018, 19, 587-589.	10.7	3
83	Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases". Annals of Surgery, 2018, 268, e9-e10.	4.2	0
84	Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2018, 267, 929-935.	4.2	3
85	Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 96-100.	2.6	157
86	Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos). Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 87-95.	2.6	220
87	Gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine, 2018, 7, 5478-5487.	2.8	19
88	Evidence that decreased expression of sinusoidal bile acid transporters accounts for the inhibition by rapamycin of bile flow recovery following liver ischemia. European Journal of Pharmacology, 2018, 838, 91-106.	3.5	1
89	Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry. Acta Oncologica, 2018, 57, 1455-1457.	1.8	3
90	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncologica, 2018, 57, 1438-1444.	1.8	78

#	ARTICLE	IF	CITATIONS
91	The Purified Extract from the Medicinal Plant <i>Bacopa monnieri</i> , Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis. <i>Cells</i> , 2018, 7, 81.	4.1	41
92	The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 653.	4.1	29
93	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	2.4	44
94	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. <i>Future Oncology</i> , 2018, 14, 2437-2459.	2.4	7
95	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3838-3844.	7.0	7
96	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	2.3	54
97	Cetuximab Alone or With Irinotecan for Resistant <i>KRAS</i> -, <i>NRAS</i> -, <i>BRAF</i> - and <i>PIK3CA</i> -wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319.	2.3	9
98	Impact of Emergent Circulating Tumor DNA <i>RAS</i> Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5602-5609.	7.0	45
99	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3500-3500.	1.6	25
100	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3534-3534.	1.6	1
101	Metastatic colorectal cancer (mCRC) and micro-satellite instability.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15510-e15510.	1.6	0
102	Advanced colorectal cancer treatment options beyond standard systemic therapy. <i>Lancet Oncology</i> , The, 2017, 18, 157-159.	10.7	8
103	Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. <i>Drugs and Aging</i> , 2017, 34, 173-189.	2.7	5
104	Capecitabine in locally advanced anal cancer, do we need randomised evidence?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 411-416.	2.4	5
105	Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. <i>International Journal of Cancer</i> , 2017, 140, 2183-2191.	5.1	33
106	Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 965-979.	2.4	6
107	Oral versus intravenous fluoropyrimidines for colorectal cancer. <i>The Cochrane Library</i> , 2017, 2017, CD008398.	2.8	23
108	Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. <i>Medical Care</i> , 2017, 55, 86-86.	2.4	0

#	ARTICLE	IF	CITATIONS
109	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	10.7	293
110	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. <i>The Cochrane Library</i> , 2017, 6, CD007047.	2.8	60
111	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. <i>Clinical Colorectal Cancer</i> , 2017, 16, e73-e88.	2.3	19
112	Synovial metastasis of the knee in a KRAS mutant rectal adenocarcinoma patient. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220008.	0.5	5
113	Role of Aquaporin 1 Signalling in Cancer Development and Progression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 299.	4.1	95
114	A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 643-643.	1.6	1
115	Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 699-699.	1.6	0
116	Patterns of care for synchronous rectal cancer with liver-only metastasis: Results from the South Australian registry of metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 701-701.	1.6	1
117	Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance. <i>New Zealand Medical Journal</i> , 2017, 130, 57-67.	0.5	4
118	Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. <i>Frontiers in Oncology</i> , 2016, 6, 241.	2.8	23
119	Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry. <i>Australian Journal of Rural Health</i> , 2016, 24, 85-91.	1.5	1
120	MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 607-615.	1.8	6
121	Human intestinal spirochetosis and its relationship to sessile serrated adenomas in an Australian population. <i>Pathology Research and Practice</i> , 2016, 212, 751-753.	2.3	4
122	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. <i>Clinical Therapeutics</i> , 2016, 38, 1376-1391.	2.5	11
123	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	1.6	52
124	Fcγ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2435-2444.	7.0	33
125	Selective internal radiation therapy for liver metastases from colorectal cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 148-154.	7.7	20
126	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2016, 68, 51-59.	2.8	56

#	ARTICLE	IF	CITATIONS
127	Liver metastases resection for gastric and esophageal tumors: is there enough evidence to go down this path?. Expert Review of Anticancer Therapy, 2016, 16, 1219-1225.	2.4	5
128	Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. Annals of Surgical Oncology, 2016, 23, 3616-3622.	1.5	16
129	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	2.6	15
130	Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. Journal of Experimental and Clinical Cancer Research, 2016, 35, 36.	8.6	60
131	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 2016, 16, 557-571.	2.4	7
132	Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncologica, 2016, 55, 480-485.	1.8	12
133	Optimal therapy for resectable rectal cancer. Expert Review of Anticancer Therapy, 2016, 16, 285-302.	2.4	0
134	Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer, 2016, 114, 505-509.	6.4	43
135	BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. Molecular Diagnosis and Therapy, 2016, 20, 75-82.	3.8	7
136	Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. Clinical Colorectal Cancer, 2016, 15, 32-36.	2.3	37
137	Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.. Journal of Clinical Oncology, 2016, 34, 256-256.	1.6	0
138	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 507-507.	1.6	7
139	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. Journal of Clinical Oncology, 2016, 34, 519-519.	1.6	4
140	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. Journal of Clinical Oncology, 2016, 34, 3538-3538.	1.6	0
141	Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17.. Journal of Clinical Oncology, 2016, 34, e15025-e15025.	1.6	0
142	Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, e15050-e15050.	1.6	0
143	Good outcomes of liver transplantation for hepatitis C at a low volume centre. Annals of Hepatology, 2016, 15, 207-14.	1.5	2
144	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE, 2015, 10, e0135599.	2.5	22

#	ARTICLE	IF	CITATIONS
145	Colorectal cancer: Metastases to a single organ. <i>World Journal of Gastroenterology</i> , 2015, 21, 11767.	3.3	233
146	Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress. <i>Molecular Medicine</i> , 2015, 21, S25-S31.	4.4	113
147	Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. <i>Cancer Medicine</i> , 2015, 4, 1461-1471.	2.8	17
148	Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?. <i>Cancer</i> , 2015, 121, 830-835.	4.1	135
149	Second-line therapy for metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 476-477.	10.7	0
150	Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5469-5479.	7.0	152
151	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3733-3740.	1.6	217
152	Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1907-1924.	3.3	11
153	Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3533-3533.	1.6	2
154	Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3586-3586.	1.6	1
155	Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3587-3587.	1.6	1
156	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14623-e14623.	1.6	2
157	Survival impact of primary tumor resection in patients (pts) with unresectable metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14675-e14675.	1.6	1
158	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 740-740.	1.6	9
159	Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. <i>World Journal of Gastroenterology</i> , 2015, 21, 5352.	3.3	5
160	Survival for patients with resectable lung metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 708-708.	1.6	0
161	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. <i>Journal of Clinical Oncology</i> , 2015, 33, 705-705.	1.6	0
162	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 566-566.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Survival improvement associated with access to biological agents: Updated results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.. Journal of Clinical Oncology, 2015, 33, e14576-e14576.	1.6	0
164	Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. Medical Journal of Australia, 2014, 201, 462-466.	1.7	7
165	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 2014, 110, 648-655.	6.4	71
166	The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta Oncologica, 2014, 53, 877-884.	1.8	8
167	Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. Colorectal Cancer, 2014, 3, 223-232.	0.8	1
168	FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncology, The, 2014, 15, e582-e583.	10.7	2
169	Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 2014, 7, 20-37.	3.2	28
170	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 2014, 14, 1477-1493.	2.4	12
171	Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Annals of Oncology, 2014, 25, 1506-1516.	1.2	186
172	The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 2014, 50, 535-543.	2.8	15
173	A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Supportive Care in Cancer, 2014, 22, 513-518.	2.2	28
174	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncology, The, 2014, 15, 569-579.	10.7	384
175	Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Supportive Care in Cancer, 2014, 22, 121-128.	2.2	97
176	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of Oncology, 2014, 25, 117-121.	1.2	57
177	Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 2014, 25, 107-116.	1.2	182
178	ASPECCT: panitumumab versus cetuximab for colorectal cancer – Authors' reply. Lancet Oncology, The, 2014, 15, e303.	10.7	2
179	PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 2014, 20, 744-753.	7.0	140
180	Can we accurately report PTEN status in advanced colorectal cancer?. BMC Cancer, 2014, 14, 128.	2.6	10

#	ARTICLE	IF	CITATIONS
181	Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 731-741.	5.1	27
182	Colorectal Cancer Survival: An Analysis of Patients With Metastatic Disease Synchronous and Metachronous With the Primary Tumor. <i>Clinical Colorectal Cancer</i> , 2014, 13, 87-93.	2.3	50
183	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3501-3501.	1.6	51
184	Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3539-3539.	1.6	2
185	Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3552-3552.	1.6	2
186	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3568-3568.	1.6	53
187	Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4101-4101.	1.6	9
188	Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 534-534.	1.6	1
189	Right (R) or left (L) primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC): Results from the south Australian registry of mCRC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 596-596.	1.6	1
190	The management of colorectal cancer (CRC) liver metastases with yttrium-90 microspheres (Y90): The south Australian (SA) experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 666-666.	1.6	1
191	Analysis of <i>KRAS/NRAS</i> mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA387-LBA387.	1.6	24
192	<i>Medical Oncology</i> , 2014, , 71-82.		0
193	Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 502-502.	1.6	1
194	The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in nontrial patients in two cancer centers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 595-595.	1.6	0
195	A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 547-547.	1.6	0
196	Patterns of care and outcomes for young patients (age ≥ 40) with metastatic colorectal cancer (mCRC): Findings from a population-based registry.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17584-e17584.	1.6	1
197	Survival outcomes for patients with metastatic colorectal cancer (mCRC) based on primary site, right (R) colon versus left (L) colon versus rectal (Rec) primary: Results from the South Australian Registry of mCRC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3540-3540.	1.6	38
198	Survival improvements associated with access to biologic agents: Results from the South Australian (SA) Metastatic Colorectal (mCRC) Registry.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17616-e17616.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3609-3609.	1.6	0
200	KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 23-6.	0.7	28
201	The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. <i>BMC Cancer</i> , 2013, 13, 242.	2.6	10
202	Management of gastric cancer in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e535-e547.	10.7	418
203	Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 239-248.	1.1	5
204	Panitumumab in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 781-793.	2.4	5
205	Current opinion on optimal treatment for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 597-611.	2.4	30
206	A population-based study of metastatic colorectal cancer in individuals aged ≥80 years. <i>Cancer</i> , 2013, 119, 722-728.	4.1	39
207	Liver only metastatic disease in patients with metastatic colorectal cancer: Impact of surgery and chemotherapy. <i>Acta Oncologica</i> , 2013, 52, 1699-1706.	1.8	21
208	Rechallenge With Oxaliplatin and Fluoropyrimidine for Metastatic Colorectal Carcinoma After Prior Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 49-52.	1.3	29
209	Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. <i>Annals of Oncology</i> , 2013, 24, 953-960.	1.2	44
210	Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. <i>Cancer Medicine</i> , 2013, 2, 277-285.	2.8	33
211	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type KRAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2477-2484.	1.6	122
212	Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?. <i>British Journal of Cancer</i> , 2013, 109, 1338-1343.	6.4	27
213	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3531-3531.	1.6	39
214	A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14506-e14506.	1.6	1
215	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14501-e14501.	1.6	0
216	Hepatic encephalopathy associated with cancer or anticancer therapy. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 11-6.	0.7	12

#	ARTICLE	IF	CITATIONS
217	Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 2012, 6, 199-209.	3.0	69
218	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. Colorectal Cancer, 2012, 1, 137-148.	0.8	1
219	Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 2012, 30, 2303-2317.	2.6	133
220	Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 247-254.	2.3	69
221	Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice. Cancer Treatment Reviews, 2012, 38, 397-406.	7.7	72
222	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer, 2012, 48, 1293-1298.	2.8	28
223	Age and treatment choices in advanced colorectal cancer. Colorectal Cancer, 2012, 1, 343-351.	0.8	0
224	A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection. Biochimie, 2012, 94, 2491-2497.	2.6	11
225	Cetuximab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2012, 12, 555-565.	2.4	32
226	“Watchful waiting” for metastatic colorectal cancer, antediluvian or an option to be considered again?. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 10-13.	1.1	11
227	Guillain-Barre syndrome in colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 205-208.	1.1	5
228	Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory <i>K-RAS</i> wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.. Journal of Clinical Oncology, 2012, 30, 386-386.	1.6	12
229	Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, 387-387.	1.6	9
230	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. Journal of Clinical Oncology, 2012, 30, 388-388.	1.6	9
231	Do patients with metastatic colorectal cancer (mCRC) with late relapse after curative surgery have a better survival?. Journal of Clinical Oncology, 2012, 30, 558-558.	1.6	0
232	Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study.. Journal of Clinical Oncology, 2012, 30, e19513-e19513.	1.6	0
233	Impact of <i>KRAS</i> and <i>BRAF</i> Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 2675-2682.	1.6	198
234	South Australian clinical registry for metastatic colorectal cancer. ANZ Journal of Surgery, 2011, 81, 352-357.	0.7	49

#	ARTICLE	IF	CITATIONS
235	Small Cell Lung Cancer: Patterns of care and their influence on survival – 25 years experience of a single Australian oncology unit. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 252-257.	1.1	6
236	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. <i>BMC Cancer</i> , 2011, 11, 313.	2.6	9
237	Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. <i>Clinical Proteomics</i> , 2011, 8, 16.	2.1	31
238	Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1465-1471.	1.6	669
239	Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. <i>Annals of Oncology</i> , 2011, 22, 1834-1838.	1.2	42
240	Reversing Hyperammonemia in Neuroendocrine Tumors. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e186-e189.	2.2	6
241	Epidemiology of neuroendocrine cancers in an Australian population. <i>Cancer Causes and Control</i> , 2010, 21, 931-938.	1.8	30
242	Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. <i>Medical Journal of Australia</i> , 2010, 193, 46-52.	1.7	89
243	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1073.	7.4	1,206
244	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3191-3198.	1.6	370
245	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4706-4713.	1.6	909
246	Antitumor Effect of Somatostatin Analogs in Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, e41-e42.	1.6	8
247	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. <i>Clinical Colorectal Cancer</i> , 2010, 9, 8-14.	2.3	7
248	Anti-“Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?. <i>Oncologist</i> , 2009, 14, 29-39.	3.7	69
249	Response to: Perioperative Morbidity Affects the Long-Term Survival in Patients Following Liver Resection for Colorectal Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 180.	1.7	0
250	Selective internal radiation therapy for liver metastases from colorectal cancer. <i>The Cochrane Library</i> , 2009, , CD007045.	2.8	19
251	Abstract C33: A two-arm phase 1 clinical trial with NPI-0052, a novel proteasome inhibitor. , 2009, , .		2
252	Contrast induced hyperthyroidism due to iodine excess. <i>BMJ Case Reports</i> , 2009, 2009, bcr0620091982-bcr0620091982.	0.5	4

#	ARTICLE	IF	CITATIONS
253	A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. <i>Investigational New Drugs</i> , 2008, 26, 89-94.	2.6	73
254	<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 1757-1765.	27.0	3,353
255	Yttrium 90 Microsphere Selective Internal Radiation Treatment of Hepatic Colorectal Metastases. <i>Archives of Surgery</i> , 2008, 143, 313.	2.2	6
256	Fluorouracil-induced Hepatic Artery Spasm Preventing Yttrium-90 Microsphere Administration. <i>Clinical Nuclear Medicine</i> , 2008, 33, 528-530.	1.3	2
257	Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. <i>Journal of Clinical Oncology</i> , 2007, 26, 102-109.	1.6	243
258	Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1702-1711.	1.3	117
259	Successfully improving access and accrual to oncology clinical trials. <i>Cancer</i> , 2007, 109, 1451-1453.	4.1	3
260	Cetuximab for the Treatment of Colorectal Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 2040-2048.	27.0	1,778
261	Chronomodulated Chemotherapy in Advanced Colorectal Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3937-3939.	1.6	2
262	BRAF Mutation in Colorectal Cancer. , 0, , .		1
263	Local Treatment Options for Unresectable Liver Metastases in Colorectal Cancer. , 0, , .		0
264	BRAF Mutation and Its Importance in Colorectal Cancer. , 0, , .		11